Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

On July 27, 2022 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported that it will report the company’s second quarter 2022 financial results on Thursday, August 4, 2022 after the close of the U.S. financial markets (Press release, Aligos Therapeutics, JUL 27, 2022, View Source [SID1234616994]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Lexicon Announces Proposed Public Offering of Common Stock

On July 27, 2022 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) ("Lexicon") reported that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the "Common Stock") (Press release, Lexicon Pharmaceuticals, JUL 27, 2022, View Source [SID1234617010]). In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of Common Stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citigroup and Piper Sandler are acting as joint book-running managers for the proposed offering.

Lexicon currently intends to use the net proceeds that it will receive from the offering, together with its existing cash and cash equivalents and short-term investments, for (i) funding pre-commercial and commercial launch activities for sotagliflozin in heart failure; (ii) funding continued development of sotagliflozin in heart failure and LX9211 in neuropathic pain; and (iii) working capital and other general corporate purposes.

A shelf registration statement on Form S-3 relating to the proposed offering was filed with the U.S. Securities and Exchange Commission ("SEC") on August 6, 2021 and declared effective by the SEC on September 14, 2021 (File No. 333-258564). A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146, or by email at [email protected]; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, Attn: Prospectus Department, by telephone at 1-800-747-3924, or by email at [email protected].

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.

City of Hope Opens the Most Advanced Comprehensive Cancer Center in Orange County, Calif., Delivering World-Renowned Treatment, Research and Cancer Cures to the Nation’s Sixth Largest County

On July 27, 2022 City of Hope, one of the largest cancer research and treatment organizations in the United States, reported that opens its visionary comprehensive cancer center in Orange County, California, creating a national model for delivering breakthrough research and pioneering treatments (Press release, City of Hope, JUL 27, 2022, View Source [SID1234617026]). The academic cancer center ushers in a new era of hope for people with cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Here, a team of some of the world’s most acclaimed physician-scientists — with expertise in lung, breast, gastrointestinal, gynecological, genitourinary, blood cancers and more — leads next-level cancer treatment and research.

City of Hope Orange County Lennar Foundation Cancer Center was made possible by a transformational $50 million gift from Lennar Foundation, the charitable arm of homebuilder Lennar Corporation. In Orange County alone, City of Hope has more than 15,000 philanthropic supporters who fuel its mission to end cancer.

A Cancer Crisis in Orange County and Across the Nation

City of Hope officials cite several reasons for an expanded presence in the region.

Nearly 20% of residents with cancer have left the area for advanced care, with many heading to City of Hope’s main campus in Duarte, California — an up to two-hour commute each way. In addition, despite its reputation for healthy living, Orange County is not immune from the 1 in 3 national statistic for cancer incidence.

In fact, the cancer incidence rate in the county is projected to increase by 18% over the next decade. Cancer risk increases with age and Orange County has a higher percentage of seniors than the U.S. average.

City of Hope, one of only 52 National Cancer Institute-designated comprehensive cancer centers in the country, is answering the call to extend its personalized care, outstanding research and lifesaving treatments closer to home for the county’s 3.2 million residents. City of Hope was recognized as the seventh "Best Hospital" for cancer in the nation, according to U.S. News & World Report’s 2022-23 Best Hospitals: Specialty Ranking.

Distinguishing clinical services at City of Hope Orange County Lennar Foundation Cancer Center will include:

Acclaimed cancer expertise: Access to City of Hope’s 575 physicians and more than 1,000 researchers and scientists who only focus on cancer.
Lifesaving clinical trials: Access to nearly 1,000 innovative Phase 1-3 clinical trials being conducted at City of Hope each year — more cancer-focused clinical trials than anywhere in the area — to provide patients with promising new treatments long before they become the standard of care.
Breakthrough treatments: Targeted immunotherapies, including CAR T cell therapy, as well as bone marrow transplants, robotic minimally invasive surgeries and MRI-guided radiation oncology. These innovations have demonstrated improved outcomes and a better quality of life for patients in treatment.
Leading-edge technology: The latest and most comprehensive suite of market-leading radiology, interventional radiology and radiation oncology equipment, providing a powerful combination of high tech and high touch.
Integrative medicine: A trailblazing integrative medicine program combining the best of Western medicine and evidence-based complementary therapies, such as acupuncture, massage and meditation.
Cancer prevention: Programs that identify people and families with elevated cancer risk utilizing genetic risk assessments, biomarker panels and environmental surveys to help manage that risk.
Early detection: Novel blood testing and imaging techniques that find cancer early, when it is still easily curable. Patients will be among the first in the nation to have access to City of Hope’s new Center for Cancer Prevention and Early Detection.
Precision medicine: Best-in-class genomic testing to profile a patient’s tumor and determine the treatment that will be most effective for their cancer.
Screening and diagnostic services: A suite of state-of-the-art imaging equipment and procedural suites, giving patients convenient access to mammography, colonoscopy, robotic bronchoscopy and other lifesaving services.
A clinical research unit: The epicenter for clinical investigational research that speeds the development of new drugs and interventions to the bedside, allowing patients to receive the latest treatments in cancer care.
Surgical oncology: An outpatient surgery department that offers advanced perioperative care, an endoscopy suite and operating rooms with robotic-assisted surgical capabilities.
Supportive care: City of Hope is a national leader in evidence-based supportive care. The Sheri & Les Biller Patient and Family Resource Center at the comprehensive cancer center in Irvine will facilitate easy access to a wide range of programs, including care navigation, survivorship programs, psychological and spiritual counseling, pain management and more.
Built For and With the Community

City of Hope Orange County Lennar Foundation Cancer Center was designed with input from more than 500 patients, their families and community members. Every feature of the cancer center — from the design of its gathering spaces to its lighting, its wall color, even its artwork selection — was intentionally chosen to promote healing and comfort and ensure patients and their families have the best care experience. Every employee is committed to delivering compassionate care, continuing the City of Hope legacy of taking patients’ hands and never letting go.

Features include:

67 spacious exam and treatment rooms.
15 consultation rooms equipped with the latest technology, allowing patients and family members to meet comfortably with their care team.
An infusion center designed around patient preferences with 43 infusion bays and 10 private infusion treatment rooms. The infusion bays feature repositionable furnishings, flexible privacy options, and panoramic views of the Saddleback mountains.
Hope Boutique, a full-service salon and specialty shopping experience with oncology-trained cosmetologists who help patients with customized cosmetology services, breast prostheses and more.
A retail and specialty pharmacy that dispenses traditional, specialty, and over-the-counter medications, alleviating the travel burden on patients for their medication needs. In addition, a compounding pharmacy provides a full evaluation of patients’ needs and prepares personalized chemotherapeutic and non-chemotherapeutic medications. Specialty-trained clinical pharmacists assist patients with medication management.
A full range of state-of-the-art laboratory services in one location, making it convenient for patients to get routine blood draws.
Feng Shui design, art galleries, a healing garden, dedicated space for family members to gather or work, and programs to care for the whole patient — mind, body, and spirit.
City of Hope Orange County’s cancer care network currently includes four regional clinics — two in Newport Beach, one in Huntington Beach and one in Irvine. The cancer center, the regional clinics and the planned hospital will create Orange County’s largest network dedicated exclusively to cancer treatment and cures.

Supporting quotes

Robert Stone, president, CEO, and Helen and Morgan Chu Chief Executive Officer Distinguished Chair, City of Hope
"City of Hope’s vision is to make leading-edge research, treatment and care accessible to more patients, families and communities across the country. Our new Orange County campus does just that, embedding an academic cancer center in the heart of a community to deliver cancer breakthroughs and innovation for generations of patients in need of our advanced care. Thank you to the teams, partners, and philanthropists who brought us to this historic day."

Annette M. Walker, president, City of Hope Orange County
"With the opening of City of Hope Orange County Lennar Foundation Cancer Center, we are delivering on our promise to the people of Orange County and changing cancer care for our family, friends and neighbors. Four years ago, we pledged to bring the most advanced cancer care to Orange County, home to 3.2 million people. As we open our cancer center’s doors, our highly committed teams join the community in celebrating the delivery of tomorrow’s lifesaving treatments to those who need them today. Hope is truly here in Orange County."

Edward S. Kim, M.D., M.B.A., physician-in-chief, City of Hope Orange County, and vice physician-in-chief, City of Hope National Medical Center
"This extraordinary cadre of preeminent cancer physician-scientists changes the Orange County landscape. Our physician roster comprises many of the best minds in the world for preventing, treating, and curing cancer. With their highly specialized expertise, distinguished history of research breakthroughs and compassionate approach, this team will transform our ability to address cancer for generations."

Marshall H. Ames, chairman, Lennar Foundation
"Giving back to the communities in which we build and developing healthier communities are core values at Lennar. The Lennar Foundation could not be prouder to have supported this new cancer center. It is gratifying to know that our gift will make a positive impact by expanding access to care, advancing research and supporting the incredible science that will one day eliminate cancer. We hope others in the philanthropic community will see the results of our efforts and join us in supporting City of Hope."

Farrah N. Khan, mayor of Irvine
"City of Hope Orange County is well-matched for Irvine, heightening our city’s reputation for pioneering innovation. This is an outstanding health care resource for the community and brings great promise to many. The center has already attracted exceptional health care professionals eager to save lives and offer our friends and neighbors a tremendous source of hope."

Leslie Bruce Amin, grateful patient
"I’ve been waiting for this day ever since City of Hope announced its plans for an Orange County campus. Whenever I connect with people navigating a cancer diagnosis, my first piece of advice is to always find a cancer-specific research center for the most advanced care. Now, right here in our community, people with cancer have the highly specialized and compassionate care they need — all in one place."

For more information or to become a volunteer or philanthropic partner of City of Hope Orange County, go to CityofHope.org/OC

Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement

On July 27, 2022 Nuvectis Pharma, Inc (Nasdaq: NVCT) ("Nuvectis" or the "Company"), a biopharmaceutical company focused on the development of precision medicines for serious conditions of unmet medical need in oncology, reported that it has entered into definitive agreements with healthcare-focused institutional and accredited investors for the issuance and sale of 1,924,689 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $8.25 per share and preferred investment option (Press release, Nuvectis Pharma, JUL 27, 2022, View Source [SID1234617156]). The investors also purchased preferred investment options to purchase up to an aggregate of 1,924,689 shares of common stock. The preferred investment options will have an exercise price of $9.65, will become exercisable commencing six months following date of issuance and will have a term of three and one-half years from the date of issuance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Gross proceeds to Nuvectis from the offering are expected to be approximately $15.9 million, before deducting placement agent fees and other offering expenses payable by the Company.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement.

The closing of the private placement is expected to occur on or about July 29, 2022, subject to the satisfaction of customary closing conditions. Nuvectis intends to use the net proceeds from the private placement for working capital and general corporate purposes

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file an initial registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock to be issued to the investors (including the shares of common stock issuable upon the exercise of the preferred investment options and pre-funded warrants).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

SHINE Submits Drug Master File for n.c.a. Lu-177

On July 27, 2022 SHINE Technologies, LLC (SHINE), a next-generation nuclear technology company, reported the company has submitted a Drug Master File (DMF) with the U.S. Food and Drug Administration for non-carrier-added lutetium-177 (Lu-177) chloride, a radiopharmaceutical at the forefront of precision cancer treatment (Press release, Shine Medical Technologies, JUL 27, 2022, View Source [SID1234618509]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In targeted cancer therapy, the cancer-killing radioisotope Lu-177 is paired with a cancer-seeking molecule to form a smart compound that directly targets and attacks cancer cells.

SHINE is the emerging leader in the production of this medical radioisotope. With its proprietary technology, SHINE intends to be the industry’s only vertically integrated producer of Lu-177, providing a reliable and scalable supply without the need for aging nuclear reactors.

The DMF submission provides confidential detailed information about facilities, procedures, or articles used in the manufacturing, processing, and storing of drugs. It is a clear commitment to the several companies that have requested letters of authorization to access SHINE’s drug master file in support of their clinical trials which are underway to fight cancer. And it is also an important step in SHINE’s path to meeting the increasing global demand for Lu-177.

"As global demand for lutetium-177 increases, SHINE is poised to scale our operations and be the preferred partner for customers seeking a high-quality, reliable supply of lutetium-177," said Chris Vessell, general manager of SHINE’s Therapeutics Division.

"We’ve been producing lutetium-177 that meets or exceeds customer specifications for some time now, and the DMF submittal represents the next step in getting our product into regular commercial use." said Greg Piefer, founder and CEO of SHINE Technologies. "We’re looking forward to growing our vertically-integrated and sustainable process to ensure the world has scalable access to these game-changing, cancer-destroying products as new therapies are approved."